Thrombopoietin receptor agonists (TPO-RAs), Eltrombopag and Romiplostim, were approved in 2008 as a second line therapy for refractory ITP and few studies have reported their efficacy in immune cytopenias, such as SLE-associated thrombocytopenia. Here, MPL is linked to autoimmune thrombocytopenic purpura.